Purple Biotech Announces Positive Preclinical Data at ESMO IO Congress 2025

Purple Biotech ( (PPBT) ) has provided an update.

On December 11, 2025, Purple Biotech reported positive preclinical data from its CAPTN-3 tri-specific antibody platform at the ESMO Immuno-Oncology Congress 2025. The data highlighted significant anti-tumor activity of two antibodies, IM1240 and IM1305, across different tumor antigens, with IM1240 showing effectiveness even in PD1-resistant models. These findings underscore the platform’s potential applicability across a range of solid tumors and support the company’s development roadmap as it prepares for key milestones in 2026.

The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.

Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CAPTN-3, CM24, and NT219, with a focus on tri-specific antibodies that engage both T cells and NK cells to induce a strong immune response within the tumor microenvironment. The company is headquartered in Rehovot, Israel.

Average Trading Volume: 7,156,560

Technical Sentiment Signal: Sell

Current Market Cap: $6.89M

For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.